DK1395283T3 - Heterolog beskyttelse induceret ved immunisering med Invaplex-vaccine - Google Patents

Heterolog beskyttelse induceret ved immunisering med Invaplex-vaccine

Info

Publication number
DK1395283T3
DK1395283T3 DK02741716T DK02741716T DK1395283T3 DK 1395283 T3 DK1395283 T3 DK 1395283T3 DK 02741716 T DK02741716 T DK 02741716T DK 02741716 T DK02741716 T DK 02741716T DK 1395283 T3 DK1395283 T3 DK 1395283T3
Authority
DK
Denmark
Prior art keywords
immunization
protection induced
heterologous protection
invaplex
invaplex vaccine
Prior art date
Application number
DK02741716T
Other languages
English (en)
Inventor
Edwin V Oaks
Kevin R Turbyfill
Original Assignee
Us Army
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Us Army filed Critical Us Army
Application granted granted Critical
Publication of DK1395283T3 publication Critical patent/DK1395283T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0283—Shigella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/82—Proteins from microorganisms
    • Y10S530/825—Bacteria

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
DK02741716T 2001-05-18 2002-05-17 Heterolog beskyttelse induceret ved immunisering med Invaplex-vaccine DK1395283T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US29215401P 2001-05-18 2001-05-18
US29249301P 2001-05-21 2001-05-21
PCT/US2002/016029 WO2002094190A2 (en) 2001-05-18 2002-05-17 Heterologous protection induced by immunization with invaplex vaccine

Publications (1)

Publication Number Publication Date
DK1395283T3 true DK1395283T3 (da) 2007-07-09

Family

ID=26967184

Family Applications (1)

Application Number Title Priority Date Filing Date
DK02741716T DK1395283T3 (da) 2001-05-18 2002-05-17 Heterolog beskyttelse induceret ved immunisering med Invaplex-vaccine

Country Status (9)

Country Link
US (1) US7258863B2 (da)
EP (1) EP1395283B1 (da)
JP (2) JP4510382B2 (da)
AT (1) ATE355853T1 (da)
AU (1) AU2002314793B2 (da)
CA (1) CA2447274C (da)
DE (1) DE60218662T2 (da)
DK (1) DK1395283T3 (da)
WO (1) WO2002094190A2 (da)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE602004025144D1 (de) 2003-11-25 2010-03-04 Us Gov Sec Army Verwendung von shigella invaplex für den transportven nukleinsäuren durch säugetier-zellmembranen in vitro und in vivo
US7481997B1 (en) 2004-02-12 2009-01-27 Montana State University Snow mountain virus genome sequence, virus-like particles and methods of use
US20080124355A1 (en) 2006-09-22 2008-05-29 David Gordon Bermudes Live bacterial vaccines for viral infection prophylaxis or treatment
CA2563214A1 (en) * 2006-10-12 2008-04-12 Institut Pasteur Shigella ipad protein and its use as a potential vaccine against shigella infection
CN101711165B (zh) * 2007-03-27 2016-02-24 以沃尔特里德军事研究所的名义,由美国陆军部部长为代表的美国政府 人造侵袭素复合物
EP2197421A1 (en) * 2007-08-31 2010-06-23 Amgen, Inc Solid-state protein formulation
US8241623B1 (en) 2009-02-09 2012-08-14 David Bermudes Protease sensitivity expression system
US9597379B1 (en) 2010-02-09 2017-03-21 David Gordon Bermudes Protease inhibitor combination with therapeutic proteins including antibodies
US8771669B1 (en) 2010-02-09 2014-07-08 David Gordon Bermudes Immunization and/or treatment of parasites and infectious agents by live bacteria
US8524220B1 (en) 2010-02-09 2013-09-03 David Gordon Bermudes Protease inhibitor: protease sensitivity expression system composition and methods improving the therapeutic activity and specificity of proteins delivered by bacteria
JP6045499B2 (ja) * 2010-10-27 2016-12-14 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 赤痢菌リポ多糖及び外膜タンパク質を含む免疫原性組成物
US9593339B1 (en) 2013-02-14 2017-03-14 David Gordon Bermudes Bacteria carrying bacteriophage and protease inhibitors for the treatment of disorders and methods of treatment
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6248329B1 (en) * 1998-06-01 2001-06-19 Ramaswamy Chandrashekar Parasitic helminth cuticlin nucleic acid molecules and uses thereof
AU1199900A (en) * 1998-09-30 2000-04-17 Walter Reed Army Institute Of Research Use of purified invaplex from gram negative bacteria as a vaccine

Also Published As

Publication number Publication date
AU2002314793B2 (en) 2007-08-02
DE60218662D1 (de) 2007-04-19
JP5149242B2 (ja) 2013-02-20
WO2002094190A3 (en) 2003-12-11
JP2009197031A (ja) 2009-09-03
DE60218662T2 (de) 2007-11-08
EP1395283B1 (en) 2007-03-07
CA2447274C (en) 2013-11-12
CA2447274A1 (en) 2002-11-28
US7258863B2 (en) 2007-08-21
EP1395283A4 (en) 2005-06-08
WO2002094190A2 (en) 2002-11-28
JP2004534762A (ja) 2004-11-18
US20020197276A1 (en) 2002-12-26
EP1395283A2 (en) 2004-03-10
JP4510382B2 (ja) 2010-07-21
ATE355853T1 (de) 2007-03-15

Similar Documents

Publication Publication Date Title
DK1395283T3 (da) Heterolog beskyttelse induceret ved immunisering med Invaplex-vaccine
ATE426412T1 (de) Adjuvante influenza-vakzine
ATE396739T1 (de) Entwicklung einer vakzine zur prävention von infektionen mit filovirus bei primaten
ATE489968T1 (de) Proteosom-liposaccharid-vakzine-adjuvans
ATE556596T1 (de) Regulierte attenuierung von lebendimpfstoffen zur verbesserung der kreuzimmunitätsschutzfunktion
ATE542829T1 (de) Impfstoff
DK1147117T3 (da) Immunologiske adjuvansforbindelser
DE59913046D1 (de) Influenzavirus-impfstoffzusammensetzung
AU2003244855A1 (en) Method to enhance an immune response of nucleic acid vaccination
DE69919754D1 (de) Verwendung von aufgereinigtem invaplex als impfstoff für gram-negativebakterien
DE60226175D1 (de) Mycobakterieller impfstoff
EP1471936A4 (en) HIV VACCINE AND METHOD OF USE
PT1112747E (pt) Vacina de salmonella que nao induz anticorpos contra flagelina ou flagelos
AU7227001A (en) Streptococcus pyogenes antigens
MX2007002659A (es) Composicion vacunal contra el virus de la hepatitis c.
ATE507286T1 (de) Immunisierung von fischen gegen virusinfektion
TW200740457A (en) Vaccine
WO2006095176A3 (en) Vaccine formulation
ATE471990T1 (de) Transkutane immunisierung gegen papillomavirus mit virusähnlichen papillomaviruspartikeln
BRPI0414073A (pt) método para induzir uma resposta imune contra infecção por rotavìrus a partir de um sorotipo de rotavìrus, e, uso de uma cepa de rotavìrus atenuado de um sorotipo
ATE431745T1 (de) Ltb4 als adjuvans für impfstoffe
ATE347905T1 (de) Lebende attenuierte bakterien zur verwendung als impfstoff
ATE495757T1 (de) Attenuierte bakterielle lebendvakzine
CY1114309T1 (el) Εμβολιο ροταϊου
UA67250A (en) Strain bovinae herpesvirus-1 "moldavian" for the preparation of vaccines and diagnosticums